This is a pipeline GLP-1 drug akin to Novo Nordisk's Wegovy or Eli Lilly's own Zepbound, targeting weight loss. A key difference is that it's an oral medication, and thus easier to administer than ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.

In a previous study, Zepbound helped people lose 20.2% of their weight, and Wegovy led to a 13.2% weight loss over 72 weeks. Still, experts say the new pill may have key benefits.

Haleon PLC HLN shares rose 1.41% to £3.53 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.69% to 9,100.77. Haleon PLC ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market ...

(Reuters) -Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to ...

While Zepbound and Wegovy are injectable drugs and not oral, as orforglipron is, that ease of administration may not be as compelling if the drug's efficacy remains significantly lower than its ...

Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots. Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Eli Lilly's pill candidate, orforglipron, led to 11% weight loss in a late-stage trial, far less than results from injectable obesity drugs.

It is a GLP-1 drug, like the popular injected weight-loss and diabetes drugs Ozempic and Wegovy, made by Novo Nordisk. Lilly’s injected drugs, Mounjaro and Zepbound, have one additional ingredient.